natgillin/translations-raw huggingface dataset:
Hence by virtue of the androgenic/progestagenic compounds of the invention, one can advantageously diminish the intrinsic detrimental effects of endogenous testosterone. 
Stoga se pomoću androgeno-progestagenih spojeva prema ovom izumu može pogodno umanjiti inherentne štetne učinke endogenog testosterona.
is hydrogen, together with R15 a -CH2 group or a double bond; 
R'? je vodik, zajedno s R'* je -CHL skupina ili dvostruka veza;
Z is -(CH)n<1>- or the bivalent radical defined above under b) 
Zje ili dvovalentni radikal gore definiran pod b) ni, 1, Rži X, jesu kao što su gore definirani, 2 (CH), o
Once the precursor has been prepared, it is treated according to the procedures of the invention, as illustrated in the following schemes, with examples given for a number of preferred products, but easily generalisable to all formula (I) compounds thanks to the normal general knowledge available to the technician of average experience in the sector. 
Jednom kad se pripremi prekursor, on se obrađuje prema postupcima ovog izuma, kao što je prikazano u slijedećim shemama, s primjerima koji su dani za brojne produkte koji su poželjni, ali se lako mogu generalizirati za sve spojeve formule (I) zahvaljujući uobičajenom općenitom znanju koje je dostupno prosječnom stručnjaku u ovom području tehnike,
The shooter, and in particular the user of long guns, is often subjected to considerable impulsive forces in the rifle stock support zone. 
Pucač, i naročito korisnik oružja s dugom cijevi, je često podvrgnut znatnim trenutnim silama u zoni oslonca za kundak puške.
The fusion protein according to claim 7, wherein flexible steric linker is selected from the group consisting of GG, E, GGGCAAACAAC (SEQ. 
Fuzijski protein prema zahtjevu 7, naznačen time da je fleksibilna sterička poveznica odabrana 1z skupine koju čine GG, E, GGGCAAACAAC (SEQ.
In this way the particle size of the thus-obtained pellets can be controlled much better, the size or the pellets is more uniform and the product fraction may exceed even 90%. 
Na taj način, veličina čestica tako dobivenih granula može se kontrolirati mnogo bolje, veličina granula je mnogo homogenija i udio frakcije u produktu može biti čak od 90%.
A pharmaceutical composition comprising a therapeutically effective amount of the salt or hydrate of claim 17 and a pharmaceutically acceptable carrier or excipient. 
Farmaceutska smjesa koja sadrži terapijski učinkovitu količinu soli ili hidrata prema bilo kojem od zahtjeva 1-14 i farmaceutski prihvatljivi nosač ili pomoćnu tvar.
a distal tip portion attached to the second end of the shaft portion. 
(c) distalni vršni dio, spojen na drugi kraj trupa.
Method according to any one of the preceding claims, characterized in that the surface reacted calcium carbonate is used in diapers, feminine hygiene products such as pads, panty liners, sanitary napkins and tampons; incontinence products; deodorant formulations; paper towels, bath tissue and facial tissue; nonwoven products such as wipes and medical products; packaging material, preferably plastic, paper or board packaging material, such as wrapping papers, packaging boards; mono and multilayer structures; permeable bags; adsorption pads; paper products, preferably paper sheets, filled and/or coated with surface-reacted calcium carbonate with or without adhesive layer; animal litter; construction and building material; preparations of compost and organic fertilizers. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se površinski reagirani kalcijev karbonat koristi u pelenama, ženskim higijenskim proizvodima kao što su ulošci, jednodnevni ulošci, higijenski ulošci i tamponi; proizvodima za inkontinenciju; formulacijama za dezodoriranje; papirnatim ručnicima, toaletnom papiru i maramicama za lice; netkanim proizvodima kao što su maramice i medicinski proizvodi; materijalima za pakiranje, poželjno u plastičnom, papirnatom ili kartonskom materijalu za pakiranje, kao što su papir za omatanje karton za pakiranje; jednoslojnim i višeslojnim strukturama; propusnima vrećicama; adsorpcijskim jastučićima; papirnatim proizvodima, poželjno listovima papira, koji su ispunjeni s površinski reagiranim kalcijevim karbonatom sa ili bez ljepljivog sloja; životinjskom otpadu; konstrukcijskom i građevinskom materijalu; pripravcima od komposta i organskim gnojivima.
The system according to any of the previous claims, wherein said separation arrangement is fixed onto said grabbing unit. 
Sustav (10) prema bilo kojem od prethodnih zahtjeva, naznačen time, da je navedeni separacijski uređaj (42) učvršćen na navedenu zahvatnu jedinicu (38).
reacting a compound of the formula (II): wherein, 
Postupak dobivanja spoja formule (I):
represents hydrogen, and their salts, solvates and solvates of the salts. 
R* predstavlja vodik, i njihove soli, solvati i solvati soli.
determining positions of the entry points based on an offset which is 1 larger than a number indicated by fourth information obtained from the bitstream; obtaining, from the bitstream, fifth information indicating whether the second slice segment is a dependent slice segment, 
određivanje položaja ulaznih točaka na temelju pomaka koji je 1 veći od broja naznačenog četvrtom informacijom dobivenom iz toka bitova; dekodiranje trenutne slike na temelju pohranjenih varijabli konteksta i ulaznih točaka.
The liquefied gas treatment system according to claim 2, wherein the sub LNG supply line (L24) is branched from the main LNG supply line (L23) at an upstream side of the high pressure pump (43). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se pomoćna linija za slanje LNG (1.24) grana od glavne linija za slanje LNG (L23) na uzvodnoj strani visokotlačne crpke (43).
reacting Compound 103 with morpholine in methanol to produce Compound 104 
reakcije Spoja 103 s morfolinom u metanolu kako bi se dobilo Spoj 104;
each q is 0 to 4; and each p is 0 to 5. The method of claim 1, wherein the improvement in aesthetic appearance is improvement in one or more of skin tone, radiance, clarity, tautness, skin firmness, plumpness, suppleness, softness, skin texture, skin texturization and moisturization, appearance of skin contours, appearance of hollow cheeks, appearance of sunken, baggy, or dark circles under eyes, skin luster, brightness, skin thickness, and skin elasticity and/or resiliency. 
Postupak prema bilo kojem od patentnih zahtjeva 1-10, naznačen time što je poboljšanje estetskog izgleda poboljšanje jednog ili više od tonusa kože, sjaja, bistrine, zategnutosti, čvrstoće kože, ispupčenosti, podatnosti, mekoće, teksture kože, teksturacije kože i vlažnosti, izgleda kontura kože, izgleda obraznih šupljina, izgleda upalih, vrećastih, ili tamnih krugova ispod očiju, sjaja kože, sjajnosti, debljine kože, i elastičnosti kože i/ili otpornosti.
In one embodiment, the present invention provides a pharmaceutically acceptable salt of The invention may further provide a pharmaceutical composition comprising a compound of formula I-k and at least one additive selected from the group consisting of antioxidants, aromatics, buffers, binders, colorants, disintegrants, diluents, emulsifiers, excipients, extenders, flavor-improving agents, gellants, glidants, preservatives, skin-penetration enhancers, solubilizers, stabilizers, suspending agents, sweeteners, tonicity agents, vehicles, and viscosity-increasing agents. 
Farmaceutska kompozicija koja sadrži spoj prema patentnom zahtjevu 1 ili 2 i najmanje jedan aditiv izabran iz grupe koju čine analgetička sredstva, antioksidanti, aromatične supstance, puferi, vezujuća sredstva, boje, sredstva za raspadanje, razblaživači, emulgatori, inertni punitelji, ekstenderi, sredstva za poboljšanje ukusa, gelirajuća sredstva, klizajuća sredstva, konzervansi, sredstva za pojačanje prodiranja kroz kožu, solubilizatori, stabilizatori, suspendirajuća sredstva, zaslađivači, sredstva za podešavanje osmotskog tlaka, nosači i sredstva za povećanje viskoznosti.
is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein when R3 is substituted heteroaryl, any substituent group of said R3 substituted heteroaryl is selected from the group consisting of NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsub stituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl; and 
Spoj za uporabu prema zahtjevu 1, naznačen time što spoj ima strukturu s formulom A ili formulom B: pri čemu su Rx i Rz neovisno odabrani iz niza koji čine vodik, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, i supstituirani ili nesupstituirani heteroaril; i Ry je neovisno odabran iz niza koji čine supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, i supstituirani ili nesupstituirani heteroaril;
The transmitter of claim 1 or 2, wherein the time interleaver is configured not to perform a time-interleaving process on the mapped constellation values corresponding to the L1 signaling data for the case that the L1 TI mode information indicates no time interleaving mode. 
Prijenosnik iz patentnog zahtjeva 1 ili 2, pri čemu je dio za umetanje vremena konfiguriran tako da ne provodi postupke umetanja vremena na mapiranim konstelacijskim vrijednostima koje odgovaraju signalnom podatku L1 u slučaju kad informacija LI TI vrste ukazuje da nema vrste umetanja vremena.
In some embodiments, the pharmaceutical composition further comprises one or more agents selected from the group consisting of aglucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione. 
U nekim oblicima, farmaceuski pripravak nadalje sadrži jedno ili više sredstava izabranih iz skupine koju čine inhibitor a-glukozidaze, inhibitor aldoza reduktaze, bigvanidi, inhibitor HMG-CoA reduktaze, inhibitor sinteze skvalena, fibrati, LDL katabolizam poboljšivači, angiotenzin konvertaza inhibitori (ACE), poboljšivači sekrecije inzulina i tiazolidindioni.
The extract for use according to claim 3 wherein said mucous membrane is the oral mucosa, gastric mucosa, intestinal mucosa, the nasal mucosa, the vaginal mucosa, the uterine mucosa, the rectal mucosa. 
Ekstrakt za uporabu u skladu s patentnim zahtjevom 3, naznačen time, da je navedena sluznica oralna sluznica, želučana sluznica, crijevna sluznica, nosna sluznica, vaginalna sluznica, sluznica maternice, rektalna sluznica.
the substituent of formula -Z-R is in the meta or para position of the phenyl group; 
supstituent formule -Z-R je u meta- ili para-položaju na fenilnoj skupini;
Cytotoxicity was not reversed by addition of purines, such as hypoxanthine, or by addition of aminoimidazole carboxamide (up to very high concentration), but was reversed by addition of leucovorin, indicating cytotoxicity was due to antagonism of a folate-related mechanism. 
Citotoksičnost nije reverzibilna na dodatak purina, kao hipoksantina, ili na dodatak aminoimidazol karboksamida (do vrlo visokih koncentracija), ali je reverzibilna na dodatak leukovorina, što indicira da je citotoksičnost uslijed antagonizma mehanizma povezanog s folatom.
Process for the preparation of a suspension of hydrogel structure having an average particle size of 600-750 nm, containing 350-875 g/l tribasic copper sulfate calcium complex of formula CuSO4x3Ca(OH)2x4H2O, and methylnaphthalenesulfonic acid sodium dimer salt as primary dispersing agent (PD), a compound of formula (I) 
Postupak za pripremu suspenzije hidrogela strukture ima prosječnu veličinu čestica od 600-750 nm, koji sadrži 350-875 g/l trobaznog bakar sulfata/kalcij kompleks formule CuSO,x3Ca(OH)x4H,0 i metilnaftalensulfonil kiselinu dimera natrijeve soli kao primarni raspršujući agent (PD), spoja formule (I)
The pharmaceutical composition according to any preceding claim wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1 -hydroxynaphthalene-2- carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate and benzenesulfonate. 
Ko-suspenzija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se farmaceutski prihvatljiva sol glikopirolata bira između fluorida, klorida, bromida, jodida, nitrata, sulfata, fosfata, formijata, acetata, trifluoracetata, propionata, butirat, laktata, citrata, tartarata, malata, maleata, sukcinata, benzoata, p-klorbenzoata, difenilacetata ili trifenilacetata, o-hidroksibenzoata, p-hidroksibenzoat, 1-hidroksinaftalen-2-karboksilata, 3-hidroksinaftalen-2-karboksilata, metansulfonata i benzensulfonata.
R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; 
Cr12-alkil, C320-heterociklil 1 Cs5.20-aril, i po izboru u odnosu na skupinu NRR', R i R' zajedno s dušikovim atomom na kojega su priključeni, tvore po izboru supstituirani 4-člani, 5-člani, 6-člani ili 7-člani heterociklički prsten;
The use according to claim 6, wherein the renin inhibitor is a δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative, or a pharmaceutically acceptable salt thereof. 
Uporaba u skladu sa zahtjevom 6, naznačena time, da inhibitor renina je derivat amida g-amino-y-hidroksi-Q-aril- alkanoične kiseline, ili je njegova farmaceutski prihvatljiva sol.
The immunogenic composition according to clause 2, wherein the conductivity of the composition is 3 mS/cm or lower. 
Imunogeni pripravak u skladu s patentnim zahtjevom 2, naznačen time što je vodljivost pripravka 3 mS/cm ili manja.
The anti-CS1 antibody for use according to any preceding claim, wherein bortezomib is administered intravenously at a dosage from approximately 0.2 mg/m2 to 2.0 mg/m2. 
HuLuc63 za uporabu u skladu s patentnim zahtjevom 12 ili 13, naznačen time da se bortezomib primjenjuje intravenoznom dozom od 1,0 mg/m2 do 1.3 mg/m2.
M is an alkaline metal ion, alkaline earth metal ion, ammonium ion, organic ammonium ion or H; a is 1 or in the case of alkaline earth metal ions 1/2. 
M je ion alkalnog metala, ion zemnoalkalnog metala, amonijak ion, organski amonijak ion i/ili H, a je 1 ili u slučaju iona zemnoalkalnih metala 1/2.
Cloning of the human cDNA encoding the A2a receptor. 
Kloniranje ljudske cCDNA dešifriranjem A2, receptora.
An extended release composition comprising bupropion, trazodone, and a pharmaceutically acceptable carrier, for use in the treatment of female sexual dysfunction (FSD), hypoactive sexual desire disorder (HSDD), female orgasm disorder (FOD), sexual interest arousal disorder (FSAD), sexual pain dsyfunction, or ED in a subject. 
Pripravak s produljenim otpuštanjem koji sadrži bupropion, trazodon, te farmaceutski prihvatljiv nosač, naznačen time da je za uporabu za liječenje ženske seksualne disfunkcije (FSD), poremećaja hipoaktivne seksualne želje ((HSDD), poremećaja orgazma kod žena (FOD), poremećaja seksualnog uzbuđenja kod žena (FSAD), seksualne disfunkcije zbog boli, ili ED kod subjekta.
An ophthalmic or otorhinolaryngological device comprising the polymeric device material of Claim 1 wherein the ophthalmic or otorhinolaryngological device is selected from the group consisting of intraocular lenses; contact lenses; keratoprostheses; corneal inlays or rings; otological ventilation tubes; and nasal implants. 
Oftalmički ili otorinolaringološki uređaj, naznačen time što sadrži polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 1, gdje se oftalmički ili otorinolaringološki uređaj bira iz skupine koju čine intraokularne leće; kontaktne leće; keratoproteze; kornealni umetci ili prsteni; otološke cijevi za propuhivanje; te nazalni usatci.
An aqueous composition according to claims 1 to 7, wherein the aluminium-salt is aluminiumhydroxide (Al(OH)3). 
Vodeni pripravak sukladno zahtjevima 1 do 7, pri čemu je aluminijeva sol aluminij hidroksid (AKOH)3).
The unit dosage form for use according to claim 1, or the use according to claim 2, wherein the unit dosage form comprises 1, 2.5, 5 or 10 mg of the compound of formula I as its dihydrochloride salt. 
Jedinični dozirni oblik za uporabu prema zahtjevu 1, ili za uporabu prema zahtjevu 2, gdje jedinični dozirmi oblik sadrži 1, 2.5, 5 ili 10 mg spoja formule I kao diklorovodičnu sol.
The invention is particularly useful during the manufacture of influenza virus vaccines, and so the invention provides a method comprising a step of mixing (i) an influenza virus antigen and (ii) an oil-in-water emulsion adjuvant that includes squalene, and wherein the method also includes a step in which squalene content is measured (a) in the adjuvant before the mixing step and/or (b) in the antigen-adjuvant mixture after the mixing step. 
Postupak koji sadrži stupanj miješanja (i) antigena virusa influence i (ii) ulje-u-vodi emulzijskog adjuvansa koji uključuje skvalen, naznačen time, da postupak također uključuje stupanj u kojem se sadržaj skvalena mjeri postupkom iz patentnog zahtjeva 1, (a) u adjuvansu prije stupnja miješanja i/ili (b) u smjesi antigena i adjuvansa nakon stupnja miješanja. .
The portable cooking and delivery system of claim 1 wherein at least one of the ovens includes an actuator moveable between a retracted configuration and an expanded configuration, wherein the actuator is selectively positionable based on a dimension of the contents of the oven to bias the contents of the oven against movement during transit of the vehicle. The portable cooking and delivery system of claim 1 wherein the oven rack has oven securement structures that removably releasably secure the ovens in the oven rack. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje (246) koji je pomičan između uvučene konfiguracije 1 rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pozicioniranje uređaja za izbacivanje na temelju dimenzija sadržina iz štednjaka, u svrhu uravnoteženja sadržaja u štednjaku, za sprečavanje njegovog pomicanja za vrijeme putovanja vozila (240).
The solid form of claim 7, characterized as having an X-ray powder diffraction pattern obtained using Cu K alpha radiation, comprising peaks expressed in 2-theta ± 0.2 at Angle (2-Theta ± 0.2) Intensity % 
Čvrsti oblik u skladu s patentnim zahtjevom 7, naznačen time, da ima difrakcijski dijagram rendgenskih zraka dobivenom korištenjem K-alfa zračenja Cu, koji sadržava vrhove izražene u 2-theta +/- 0,2 pri Kut (2-theta +/- 0,2) Intenzitet (%)
PCT International Publication No. 
Broj međunarodne objave:
The HCl salt was isolated after reflux in HCl. 
HCI sol se izolira nakon refluksa u HCL.
Accordingly, the discovery of compounds that are selective to the SGLT2 transporter may demonstrate a utility for the treatment or prevention of diseases or disorders associated with control of plasma glucose levels, such as diabetes. 
Prema tome, otkriće spojeva koji su selektivni za SGLT2 transporter može pokazati korist za liječenje ili prevenciju bolesti ili poremećaja povezanih sa kontrolom nivoa glukoze u plazmi, kao što je dijabetes.
The compound of or therapeutically acceptable salt thereof claim 1, wherein 
(IIla) . ili njegova terapeutski prihvatljiva sol pri čemu
The process of claim 33 further comprising a deprotection reaction when ring A is wherein Ra is a silyl protecting group, to generate a compound of Formula (I), wherein ring A is; 
Postupak prema zahtjevu 33 naznačen time da dodatno sadrži reakciju deprotekcije kada prsten A je (ili (d) naznačen time da R* je silil zaštitna skupina, da de dobije spoj sa formulom (1), pri čemu prsten A je;
is -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; 
R; je -H, opcionalno supstituirani alkil, opcionalno supstituirami alkenil, opcionalno supstituirani alkinil, opcionalno supstituirani_cikloalkil, opcionalno supstituirani cikloalkenil, opcionalno supstituirani heterociklil, opcionalno supstituirani aril, opcionalno supstituirani heteroaril, opcionalno supstituirani aralkil, ili opcionalno supstituirani heteraralkil;
The ruminant compound feed according to claim 9, wherein the emulsifier is a non-ionic emulsifier, more preferably it has a HLB value of at least 5, preferably at least 7, more preferably at most 14, still more preferably it is a castor oil based emulsifier and most preferably the amount of emulsifier in the feed is 0.01-2.0%, preferably 0.02-1.0%, still more preferably 0.02-0.5%, most preferably 0.02-0.06% by weight. 
Životinjska hrana za preživače prema zahtjevu 14, naznačeno time da je emulgator ne-ionski emulgator, poželjnije da ima HLB vrijednost u iznosu od barem 5, poželjno barem 7, poželjnije barem 14, još poželjnije da je emulgator na bazi ricinusovog ulja i najpoželjnije da je udio emulgatora u životinjskoj hrani od 0,01 do 1,0%, poželjno od 0,02 do 0,2%, najpoželjnije od 0,02 do 0,05% težine.
that it comprises an elastic material; 
- sastoji se od elastičnog materijala;
The composition of Claim 10 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. 
Pripravak iz zahtjeva 10, pri čemu je interferon izabran između interferona a2B, pegiliranog interferona a, konsenzus interferona, interferona a2A i limfoblastoidnog interferona t.
The anti-CD40 antibody or antigen-binding fragment thereof of claim 1 or the use of claim 2, wherein said antigen-binding fragment of said anti-CD40 antibody is selected from the group consisting of an Fab fragment, an F(ab')2 fragment, an Fv fragment, and a single-chain Fv fragment. 
Antitijelo za uporabu prema Patentnom zahtjevu 7, naznačeno time, što je spomenuti fragment izabran iz grupe koju čine Fab fragment, F(ab')2 fragment, Fv fragment i jednolančani Fv fragment.
Iota-carrageenan for use as claimed in any one of claims 1 to 10, wherein the composition is attached by either coating or impregnation to a solid surface of a hygiene or sanitary item, particularly of a hygiene or sanitary glove, tissue or paper, especially a nasal tissue or paper, a cotton swab, dust mask or sanitary or medical facial mask. 
Jota-karagenan namijenjen upotrebi u skladu s bilo kojim od patentni zahtjeva 1 do 10, naznačen time što je pripravak vezan bilo oblaganjem ili impregniranjem na čvrstu površinu higijenskog ili sanitarnog artikla, osobito higijenske ili sanitarne rukavice, maramice ili papira, osobito maramice ili papira za nos, pamučne vate, maske za prašinu ili sanitarne ili medicinske maske za lice.